Utilization of dexrazoxane in patients treated with doxorubicin: a retrospective, propensity matched analysis of cardiac function and toxicity

IntroductionDexrazoxane (DZR) has been used to prevent cardiotoxicity from doxorubicin (DOX), particularly in younger patients with cancer and those with pre-existing cardiac dysfunction. Herein, we sought to further define the role of DZR by evaluating its capacity to mitigate cardiotoxicity in pat...

Full description

Saved in:
Bibliographic Details
Main Authors: Zachary M. Neiman, Carlo S. Legasto, Alan K. Chin, Tiffany Guan, Brian C. Schulte
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1621409/full
Tags: Add Tag
No Tags, Be the first to tag this record!